NASDAQ:AYTU Aytu BioPharma (AYTU) Stock Price, News & Analysis $2.50 +0.03 (+1.21%) Closing price 04:00 PM EasternExtended Trading$2.50 0.00 (-0.20%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aytu BioPharma Stock (NASDAQ:AYTU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aytu BioPharma alerts:Sign Up Key Stats Today's Range$2.49▼$2.5450-Day Range$2.31▼$2.7352-Week Range$1.22▼$3.07Volume7,727 shsAverage Volume64,162 shsMarket Capitalization$26.83 millionP/E RatioN/ADividend YieldN/APrice Target$9.33Consensus RatingHold Company Overview Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics. Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms. The company also offers NeoProfen (ibuprofen lysine injection) for the closure of patent ductus arteriosus in premature infants and markets an FDA-authorized rapid antigen COVID-19 self-test under license. Aytu’s products are generally distributed through specialty pharmacies, hospital networks and national wholesale distributors across the United States. Under the leadership of President and Chief Executive Officer Josh Disbrow, Aytu continues to explore licensing partnerships and in-licensing opportunities to expand its pipeline. In addition to its commercial business, the company holds exclusive rights to clinical-stage candidates addressing chronic kidney disease and other orphan indications. Aytu’s management team brings experience in life sciences finance, regulatory affairs and commercial operations as it seeks to grow both its therapeutic and diagnostic offerings and extend its reach through strategic collaborations.AI Generated. May Contain Errors. Read More Aytu BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreAYTU MarketRank™: Aytu BioPharma scored higher than 36% of companies evaluated by MarketBeat, and ranked 660th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingAytu BioPharma has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Upside PotentialAytu BioPharma has a consensus price target of $9.33, representing about 273.3% upside from its current price of $2.50.Amount of Analyst CoverageAytu BioPharma has only been the subject of 2 research reports in the past 90 days.Read more about Aytu BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aytu BioPharma are expected to grow in the coming year, from ($0.69) to $0.30 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aytu BioPharma is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aytu BioPharma is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAytu BioPharma has a P/B Ratio of 1.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aytu BioPharma's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.92% of the float of Aytu BioPharma has been sold short.Short Interest Ratio / Days to CoverAytu BioPharma has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Aytu BioPharma has recently decreased by 0.23%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAytu BioPharma does not currently pay a dividend.Dividend GrowthAytu BioPharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Aytu BioPharma this week, compared to 2 articles on an average week.Search Interest2 people have searched for AYTU on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Aytu BioPharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aytu BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders4.90% of the stock of Aytu BioPharma is held by insiders.Percentage Held by Institutions33.49% of the stock of Aytu BioPharma is held by institutions.Read more about Aytu BioPharma's insider trading history. Receive AYTU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AYTU Stock News HeadlinesAytu BioPharma Inc. (NASDAQ:AYTU) Given Average Rating of "Hold" by AnalystsMay 2, 2026 | americanbankingnews.comFavourable Signals For Aytu BioPharma: Numerous Insiders Acquired StockApril 30, 2026 | finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 8 at 1:00 AM | American Alternative (Ad)Aytu BioPharma outlines EXXUA launch strategy and expects breakeven at $17.3M quarterly net revenue as ADHD portfolio remains resilientFebruary 4, 2026 | seekingalpha.comAytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navigating Challenges and ...February 4, 2026 | finance.yahoo.comAytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 earnings call transcriptFebruary 4, 2026 | msn.comAytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial ResultsFebruary 3, 2026 | finanznachrichten.deAytu BioPharma AYTU Q2 2026 Earnings TranscriptFebruary 3, 2026 | finance.yahoo.comSee More Headlines AYTU Stock Analysis - Frequently Asked Questions How have AYTU shares performed this year? Aytu BioPharma's stock was trading at $2.60 at the start of the year. Since then, AYTU shares have decreased by 3.8% and is now trading at $2.50. How were Aytu BioPharma's earnings last quarter? Aytu BioPharma Inc. (NASDAQ:AYTU) issued its quarterly earnings data on Thursday, November, 13th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.02. The company had revenue of $13.89 million for the quarter, compared to the consensus estimate of $17.92 million. Aytu BioPharma had a negative net margin of 39.02% and a negative trailing twelve-month return on equity of 28.22%. Read the conference call transcript. When did Aytu BioPharma's stock split? Aytu BioPharma's stock reverse split before market open on Tuesday, August 29th 2017.The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Aytu BioPharma's major shareholders? Aytu BioPharma's top institutional investors include Dimensional Fund Advisors LP (0.41%). Insiders that own company stock include Joshua R Disbrow and Greg Pyszczymuka. View institutional ownership trends. How do I buy shares of Aytu BioPharma? Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aytu BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aytu BioPharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), GE Aerospace (GE), Adobe (ADBE). Company Calendar Last Earnings11/13/2025Today5/08/2026Next Earnings (Estimated)5/13/2026Fiscal Year End6/30/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 AYTU's financial health is in the Green zone, according to TradeSmith. AYTU has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AYTU CIK1385818 Webaytubio.com Phone(720) 437-6580FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Price Target for Aytu BioPharma$9.33 High Price Target$13.00 Low Price Target$7.00 Potential Upside/Downside+273.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.56 million Net Margins-39.02% Pretax Margin-38.70% Return on Equity-28.22% Return on Assets-5.20% Debt Debt-to-Equity Ratio0.70 Current Ratio1.16 Quick Ratio1.03 Sales & Book Value Annual Sales$62.64 million Price / Sales0.43 Cash Flow$0.37 per share Price / Cash Flow6.82 Book Value$2.11 per share Price / Book1.18Miscellaneous Outstanding Shares10,733,000Free Float10,207,000Market Cap$26.83 million OptionableNot Optionable Beta0.28 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AYTU) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Iran War Just Broke the Gold MarketThe Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredElon’s AI supercomputer just went live. Here’s my #1 stock.Is Elon about to trigger another 315X opportunity? Elon gave Tesla investors the chance to make more than 3...InvestorPlace | SponsoredYour book attachedBill Poulos is offering a temporary backdoor link that skips the order page for his Simple Options Trading For...Profits Run | SponsoredThe $25 trillion opportunity unfolding nowWall Street is calling it a 25 trillion revolution - and it's already underway. Driven by a breakthrough techn...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aytu BioPharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aytu BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
